LXEO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.301

-61.6%

-0.332

-66.5%

-0.347

-48.79%

Estimates Revision

The market is revising No Change the revenue expectations for Lexeo Therapeutics, Inc. (LXEO) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 28.54%.

EPS Estimates for FY2025

Revise Downward

-19.9%

In Past 3 Month

Stock Price

Go Up

+28.54%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast LXEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXEO is 19.57 USD with a low forecast of 13.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

13.00

Averages

19.57

High

30.00

Current: 0.000

Low

13.00

Averages

19.57

High

30.00

Raymond James

initiated

$25

2025-12-17

Reason

Raymond James

Price Target

$25

2025-12-17

initiated

Reason

Raymond James initiated coverage of Lexeo Therapeutics with a Strong Buy rating and $25 price target. Based on strong results from two Phase 1/2 clinical trials and constructive feedback from FDA, Lexeo's lead asset LX2006 for cardiomyopathy associated with Friedreich's Ataxia is "well-positioned for success" in its pivotal trial, the analyst argues. The firm anticipates the stock will move next year on a finalized pivotal protocol with FDA and initial proof of concept data on a second, unmodeled gene therapy asset, LX2020, notes the analyst, who models LX2006 revenue of $14.1M in FY27 and growing to $805.3M in FY32.

Cantor Fitzgerald

NULL -> Overweight

initiated

$19

2025-11-20

Reason

Cantor Fitzgerald

Price Target

$19

2025-11-20

initiated

NULL -> Overweight

Reason

Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with an Overweight rating and $19 price target.

Cantor Fitzgerald

Overweight

initiated

$19

2025-11-20

Reason

Cantor Fitzgerald

Price Target

$19

2025-11-20

initiated

Overweight

Reason

Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with an Overweight rating and $19 price target. Lead asset LX2006 is an AAVrh10-based gene therapy for Friedreich's ataxia cardiomyopathy in pre-pivotal development, and Lexeo is also developing LX2020 as an AAVrh10-based gene therapy in PKP2 arrhythmogenic cardiomyopathy, the analyst tells investors in a research note. The firm applauds management's approach to be transparent with frequent, quarterly safety updates, and thinks Lexeo could prove itself to be a leading cardiac-gene therapy company.

H.C. Wainwright

Buy

maintain

$13

2025-11-03

Reason

H.C. Wainwright

Price Target

$13

2025-11-03

maintain

Buy

Reason

H.C. Wainwright reiterated a Buy rating and $13 price target on Lexeo Therapeutics, saying Monday's selloff looks "highly unwarranted" given the company's data integrity and forward-aligned FDA dialogue. Lexeo's concurrent-control design is exactly what the modern FDA wants to see, not what it is pushing back on, the analyst says, adding that Lexeo's alignment was reached under a new guard, positioning it firmly within today's regulatory expectations. The firm also noted that it views Lexeo as one of the few gene-therapy developers that pre-emptively designed to the FDA's post-reorganization, post-Marks standard for evidence generation, and that the roughly 10% selloff reflects confusion between the regulatory tightening and regulatory alignment and creates a clear buying opportunity.

H.C. Wainwright

Buy

downgrade

$15 -> $13

2025-10-21

Reason

H.C. Wainwright

Price Target

$15 -> $13

2025-10-21

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Lexeo Therapeutics to $13 from $15 and keeps a Buy rating on the shares. The firm cites share dilution from the most recent equity raise for the target cut.

Leerink

Mani Foroohar

Outperform

downgrade

$20 -> $18

2025-10-17

Reason

Leerink

Mani Foroohar

Price Target

$20 -> $18

2025-10-17

downgrade

Outperform

Reason

Leerink analyst Mani Foroohar lowered the firm's price target on Lexeo Therapeutics to $18 from $20 and keeps an Outperform rating on the shares. The firm notes the company announced a secondary offering and concurrent private placement with gross proceeds of $135M, alongside additional LX2020 PKP2 data. Leerink says that shoring up the balance sheet ahead of pivotal FACM trial initiation and additional PKP2 data makes sense to the firm, and keeps the focus on Lexeo's data rather than any balance sheet overhang.

Valuation Metrics

The current forward P/E ratio for Lexeo Therapeutics Inc (LXEO.O) is -7.11, compared to its 5-year average forward P/E of -3.78. For a more detailed relative valuation and DCF analysis to assess Lexeo Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.78

Current PE

-7.11

Overvalued PE

-1.92

Undervalued PE

-5.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.06

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.38

Undervalued EV/EBITDA

-4.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LXEO News & Events

Events Timeline

No data

News

8.0

01-09NASDAQ.COM

IBM and LXEO Options Show Significant Volume Surge

7.5

01-08NASDAQ.COM

Lexeo Therapeutics Partners with J&J to Advance Gene Therapy for Cardiovascular Diseases

4.0

2025-12-18Benzinga

Valvoline Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations

People Also Watch

Frequently Asked Questions

What is Lexeo Therapeutics Inc (LXEO) stock price today?

The current price of LXEO is 10.54 USD — it has increased 11.3 % in the last trading day.

What is Lexeo Therapeutics Inc (LXEO)'s business?

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

What is the price predicton of LXEO Stock?

What is Lexeo Therapeutics Inc (LXEO)'s revenue for the last quarter?

Lexeo Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Lexeo Therapeutics Inc (LXEO)'s earnings per share (EPS) for the last quarter?

Lexeo Therapeutics Inc. EPS for the last quarter amounts to -0.33 USD, decreased -62.92 % YoY.

What changes have occurred in the market's expectations for Lexeo Therapeutics Inc (LXEO)'s fundamentals?

How many employees does Lexeo Therapeutics Inc (LXEO). have?

Lexeo Therapeutics Inc (LXEO) has 72 emplpoyees as of January 11 2026.

What is Lexeo Therapeutics Inc (LXEO) market cap?

Today LXEO has the market capitalization of 769.29M USD.